KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Consolidated Net Income: 2011-2024

Historic Consolidated Net Income for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$4.8 million.

  • Esperion Therapeutics' Consolidated Net Income fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Consolidated Net Income of -$4.8 million as of FY2024, which was up 97.74% from -$214.5 million recorded in FY2023.
  • Esperion Therapeutics' 5-year Consolidated Net Income high stood at -$4.8 million for FY2024, and its period low was -$273.1 million during FY2021.
  • In the last 3 years, Esperion Therapeutics' Consolidated Net Income had a median value of -$214.5 million in 2023 and averaged -$151.9 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Consolidated Net Income crashed by 89.55% in 2021, and later skyrocketed by 97.74% in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Consolidated Net Income stood at -$144.1 million in 2020, then plummeted by 89.55% to -$273.1 million in 2021, then rose by 13.47% to -$236.3 million in 2022, then increased by 9.21% to -$214.5 million in 2023, then spiked by 97.74% to -$4.8 million in 2024.